Arkolith/Insider Trading/PRLD/Form 4

Combs Andrew

Chief Chemistry OfficerPrelude Therapeutics Inc (PRLD) · full profile →Form 4 · filed Mar 27, 2025
Net Buying
Open-Market Buys
$69K
Open-Market Sells
$0
Net Open-Market Flow
$69K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 25, 2025Buy(P)100K$0.69$69K480K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-25-002779) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML